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ABSTRACT
Introduction: The aim of this study was to
compare the accuracy of 5 blood glucose
monitoring systems (BGMSs; CONTOURPLUS
[CP], Accu-Chek Active [ACA], Accu-Chek
Performa [ACP], FreeStyle FreedomTM [FF],
OneTouch SelectSimpleTM [OTSS]).
Methods: Study staff tested fingerstick samples
from 106 subjects aged C18 years using the
5 BGMSs. Some samples were modified to
achieve blood glucose concentrations
throughout the measuring range. The primary
endpoint was comparison of the mean absolute
relative difference (MARD) from the reference
value (Yellow Springs Instruments [YSI]) across
the overall tested glucose range. Other
endpoints were MARD in the low (B80 mg/dL
[B4.4 mmol/L]), middle (81–180 mg/dL
[4.5–10.0 mmol/L]), and high ([180 mg/dL
[ 10.0 mmol/L]) glucose ranges, and MARD for
unmodified samples in the overall glucose
range.
Results: CONTOURPLUS had a statistically
significantly lower MARD than all BGMSs
across the overall tested range (27–460 mg/dL
[1.5–25.5 mmol/L]) and in the high glucose
range. In the low glucose range, CP had a lower
MARD than all BGMSs, which was statistically
significant except for ACP. For unmodified
samples across the overall tested range, CP had
a lower MARD than all BGMSs and was
statistically significantly lower except for ACA.
Conclusions: CONTOURPLUS had the lowest
mean difference from the reference values (by
MARD) when compared with other BGMSs
across multiple glucose ranges with modified
and unmodified samples.
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INTRODUCTION
Self-monitoring of blood glucose (SMBG) is an
important component of a comprehensive
diabetes care plan and can help people with
diabetes achieve glycemic control [1, 2]. The
accuracy of SMBG results is an important
consideration because these results are often
used to make diabetes management decisions
[3–7]. SMBG helps detect hypoglycemia and
hyperglycemia and helps reduce glycemic
variability, which has been shown to have an
impact on diabetes complications [8–10].
Because SMBG results can be used to guide the
self-care practices of people with diabetes, it is
important for the blood glucose monitoring
system (BGMS) to provide accurate results [3–5].
Performance evaluations of BGMSs for
regulatory purposes may include the use of
criteria of the International Organization for
Standardization (ISO 15197:2013 [11]).
Furthermore, Parkes-Consensus Error Grid
analysis [12] may be used to evaluate the
clinical impact of the error in measurement of
blood glucose.
ISO guidelines were developed based on the
need to establish requirements that result in
acceptable performance of BGMSs and to
specify procedures for demonstrating
conformance. According to ISO guidelines,
accuracy is based on the absolute difference of
BGMS results from the reference result in lower
glucose ranges, and the absolute relative
(percent) difference of BGMS results from the
reference result in higher glucose ranges; ISO
requirements state that C95% of results shall
fall within specified margins of error [11, 13].
Specifically, the ISO 15197:2003 standard
required that C95% of results were within
±15 mg/dL (±0.8 mmol/L) or ±20% of the
reference result for samples with glucose
concentrations \75 mg/dL (\4.2 mmol/L) and
C75 mg/dL (C4.2 mmol/L), respectively [13].
Tighter accuracy criteria were adopted with
the ISO 15197:2013 standard, which requires
that C95% of results fall within ±15 mg/dL
(±0.8 mmol/L) or ±15% of the reference result
for samples with glucose concentrations
\100 mg/dL (\5.6 mmol/L) and C100 mg/dL
(C5.6 mmol/L), respectively [11]. However,
even though commercially available BGMSs
have met the accuracy criteria required to be
permitted to enter a specific regional market,
differences exist in overall performance [14–18].
While individual system performance
evaluations commonly use ISO criteria to
assess accuracy, other types of analyses are
well suited for evaluating comparative
accuracy among multiple meters. For example,
mean absolute relative difference (MARD) is a
useful measure for comparing the accuracy of
multiple meters in a single study, as it
represents the mean difference from the
laboratory reference value of all (100%) the
glucose measurements obtained [19, 20]. Thus,
a lower MARD value indicates better accuracy
when comparing multiple BGMSs.
The CONTOURPLUS (CP) BGMS uses test
strips with a flavin adenine dinucleotide-glucose
dehydrogenase enzyme, a proprietary electron
mediator and an advanced algorithm, which, in
combination, form the technical basis for the
system’s accuracy. This study compared the
accuracy of the CP BGMS, as measured by
MARD, with 4 other BGMSs (Accu-Chek
Active [ACA], Accu-Chek Performa [ACP],
FreeStyle FreedomTM [FF], and OneTouch
SelectSimpleTM [OTSS]). The primary endpoint
of the study was to evaluate differences in
accuracy between the CP BGMS and the
4 other BGMSs across the overall tested glucose
range; additional objectives were to evaluate
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differences in accuracy between the BGMSs in
the low (B80mg/dL [B4.4 mmol/L]), middle
(81–180 mg/dL [4.5–10.0 mmol/L]), and high
([180 mg/dL [ 10.0 mmol/L]) glucose ranges.
METHODS
Study Design
This sponsor-investigator study was conducted
by trained personnel in a Bayer facility where
industry standards related to Good Clinical
Practice and Good Laboratory Practice were
followed. Institutional Review Board approval
was obtained from the Allendale Investigational
Review Board for the protocol, informed
consent forms, and all study documents
requiring such approval. Each subject
completed the informed consent process
before participating in the study. The study
enrolled subjects aged C18 years with diabetes
([90%) and without diabetes (B10%). The study
consisted of a single study visit, approximately
30 min in length. Subjects were excluded from
the study if they had a blood-borne infection,
hemophilia or other bleeding disorder, or were
pregnant.
Study staff performed a single fingerstick on
each subject and tested all 5 BGMSs (CP [Bayer
HealthCare LLC, Diabetes Care, Tarrytown, NY,
USA], ACA [Roche Diagnostics, Indianapolis,
IN, USA], ACP [Roche Diagnostics, Indianapolis,
IN, USA], FF [Abbott Diabetes Care, Inc,
Alameda, CA, USA], and OTSS [LifeScan, Inc.,
Milpitas, CA, USA]) directly from the subject’s
fingertip, wiping the finger in between each
BGMS test. Second and third fingerstick blood
samples taken from each subject were collected
in microtubes containing lithium heparin
anticoagulant. These samples were modified to
achieve blood glucose concentrations
throughout the measuring range. Blood
samples were glycolyzed in a 32C water bath
for a maximum of 10 h to lower the glucose
concentration (mean ± standard deviation [SD]
duration 3.79 ± 1.53 h; range 0.30–7.33 h), and
standard glucose solution was added to raise the
glucose concentration.
For testing the modified blood samples, a
fresh drop of blood was removed from the tube
just prior to each meter test (after being placed
on Parafilm or similar) and was tested promptly
to avoid evaporation. All blood samples were
tested on the 5 BGMSs using a test order
rotation throughout the study. A single test
strip lot per meter system was used for testing
all samples.
After the meter tests, the remaining blood in
the tube was immediately centrifuged for testing
on a Yellow Springs Instruments (YSI) laboratory
glucose analyzer (YSI Life Sciences, Inc., Yellow
Springs, OH, USA). The time from the first meter
test to centrifugation was not to exceed 15 min
(mean ± SD interval 2.3 ± 1.2 min; range
1–7 min). The accuracy and precision of the
2 YSI analyzers were monitored throughout the
study using 6 serum traceability control levels
that spanned the range from 23.5 mg/dL
(1.3 mmol/L) to 585 mg/dL (32.5 mmol/L). The
target glucose levels for the controls had been
previously determined using a reference method
traceable to the National Institute of Standards
and Technology Standard Reference Material
965a Glucose in Frozen Human Serum
(aqueous New England Reagents Laboratory
Glucose Standards) [21].
Assessments and Analyses
An analysis of variance (ANOVA) was performed
for the absolute value of the relative percent
difference between BGMS and reference results
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to compare the MARD between meter systems
for all tested samples (both modified and
unmodified) across a number of blood glucose
ranges (B80 mg/dL [B4.4 mmol/L], 81–180
mg/dL [4.5–10.0 mmol/L], [180 mg/dL [ 10.0
mmol/L], and across the overall range). Glucose
oxidase–based systems (e.g., OTSS) are sensitive
to oxygen in the sample, and sample
modification may affect the concentration of
oxygen in the sample. Thus, MARD analysis was
also performed for unmodified samples only.
Samples were not included in the analyses if
they did not fall within the hematocrit range
(30–55%) or glucose concentration range
(20–500 mg/dL [1.1–27.8 mmol/L] as measured
by YSI) to accommodate the combined
specifications of all 5 BGMSs. The majority of
BGMSs in this study claimed a low glucose limit
of 20 mg/dL (1.1 mmol/L) in their labeling (all
BGMSs except CP and ACA, both of which have
a low glucose limit of 10 mg/dL [0.6 mmol/L]).
P values comparing each BGMS to the CP
BGMS were determined using post-ANOVA
contrasts. P values\0.0125 are considered
significant (Bonferroni adjustment to a). For
each BGMS, a modified Bland-Altman plot of
the difference of BGMS results from the YSI
reference results was constructed. ISO
15197:2013 accuracy criteria [11] were
represented by dashed lines. The points were
differentiated by unique symbols, denoting
whether the blood samples were modified or
unmodified. Measured glucose values most
similar to YSI reference values were indicated
by points nearest the horizontal line (y = 0). To
assess clinical accuracy, Parkes-Consensus Error
Grid analysis [12] was performed for each
BGMS. Adverse events (AEs) were monitored
throughout the study.
Compliance With Ethics Guidelines
All procedures followed were in accordance with
the ethical standards of the responsible committee
on human experimentation (institutional and
national) and with the Helsinki Declaration of
1975, as revised in 2000 and 2008. Informed
consent was obtained from all subjects for
inclusion in the study. Institutional Review Board




A total of 106 subjects aged 18–84 years were
enrolled and completed the study. Most
subjects (n = 90) had type 2 diabetes,
8 subjects had type 1 diabetes, 2 subjects had
diabetes of unknown type, and 6 subjects did
not have diabetes (Table 1).
Blood Samples
For each BGMS, 105 unmodified blood samples
and 209 modified capillary blood samples were
analyzed. Unmodified and modified blood
samples from 1 subject were not included in the
accuracy analyses because hematocrit was[55%,
which is outside the hematocrit range that is
specified in the labeling for 2 of the 4 BGMSs
tested (ACA and OTSS). The third sample from
another subject was glycolyzed, resulting in a YSI
value of 12.3 mg/dL (0.68 mmol/L). This sample
was, therefore, not evaluable because its YSI value
was below the minimum glucose limit of 20
mg/dL (1.1 mmol/L) for all BGMSs combined.
380 Diabetes Ther (2015) 6:377–388
The overall glucose concentration range of
analyzed samples was 27 mg/dL (1.5 mmol/L) to
460 mg/dL (25.5 mmol/L) as measured by YSI.
The hematocrit range of the blood samples was
34.5% to 55.0%, with a mean of 43.3%. In
1 case of testing of the FF BGMS, even though
the glucose concentration of the blood sample
was greater than 20 mg/dL (1.1 mmol/L) as
measured by the YSI analyzer, the meter did
not produce a numerical reading; rather, a
‘‘low’’ message was displayed. As per protocol,
a result of 20 mg/dL (1.1 mmol/L) was assigned
to include the result in numerical analyses. The
largest numerical value representing the lower
limit of the glucose concentration range for any
of the meters tested in the study was 20 mg/dL
(1.1 mmol/L); thus, setting the value to 20
mg/dL (1.1 mmol/L) assigned the meter that
produced the non-numerical result the
smallest possible error relative to the YSI
value. The remaining BGMSs tested in the
study displayed a numerical result for all
samples.
Accuracy
Mean absolute relative difference comparisons
to the CP BGMS are shown in Table 2. Analysis
of the primary endpoint showed that the CP
BGMS had a statistically significantly lower
MARD than the other BGMSs across the
overall glucose range tested (27–460 mg/dL
[1.5–25.5 mmol/L] as measured by YSI). In the
high glucose range ([180 mg/dL [ 10.0
mmol/L]), the CP BGMS had a statistically
significantly lower MARD than all BGMSs
tested. In the low (B80 mg/dL [B4.4 mmol/L])
and middle (81–180 mg/dL [4.5–10.0 mmol/L])
glucose ranges, the CP BGMS had a lower MARD
than all BGMSs tested and was statistically
significantly lower than all systems except for
ACP.
The MARD analysis using only unmodified
samples revealed that the CP BGMS had a lower
MARD than all BGMSs tested in the overall
glucose range (45–460 mg/dL [2.5–25.5
mmol/L] as measured by YSI) and was
Table 1 Subject demographic and baseline characteristics




Type of diabetes, n (%)a
Type 1 8 (8)
Type 2 90 (85)
Type unknown 2 (2)
Do not have diabetes 6 (6)
Age, y
Mean (range) 57.9 (18–84)
Race, n (%)
White/Caucasian 87 (82)
Black/African American 10 (9)
American Indian/Alaskan Native 2 (2)
Other 7 (7)
Duration of diabetes, n (%)b
1–3 mo 2 (2)
4–6 mo 2 (2)
7–12 mo 1 (1)
13 mo–2 y 5 (5)
3–5 y 11 (11)
6–10 y 25 (25)
[10 y 54 (54)







Did not test 3 (3)
y years, mo months, SMBG self-monitoring of blood glucose
a Percentages may not total 100% because of rounding
b Only for subjects with diabetes, n = 100
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statistically significantly lower than all systems
except for the ACA BGMS (Table 2).
Modified Bland-Altman plots for each BGMS
are shown in Fig. 1a–e, with the YSI value on the
x-axis and the signed difference between the
meter result and the YSI result on the y-axis.
By Parkes-Consensus Error Grid analysis,
99.7% (313/314) of CP BGMS results, 98.1%
(308/314) of ACA BGMS results, and 99.4%
(312/314) of ACP BGMS results were within
Zone A, with the remainder within Zone B
(Table 3). For the FF BGMS and the OTSS BGMS,
94.3% (296/314) of results were within Zone A,
with the remainder within Zone B (Table 3).
Safety
There were 3 mild, anticipated, non–device-
related AEs; the 3 subjects had hypoglycemia
(blood glucose value \60 mg/dL [\3.3
mmol/L]). All AEs were managed, resolved,
and documented.
DISCUSSION
Using an accurate BGMS may help people with
diabetes to use their blood glucose values from
SMBG to make better informed decisions about
their diabetes management [3–7]. MARD
analysis is useful for comparing the accuracy
of multiple meters in a single study [19]. In this
study, the CP BGMS had a statistically
significantly lower MARD in the overall
glucose range (27–460 mg/dL [1.5–25.5
mmol/L]) than all BGMSs tested. The CP
BGMS also had the lowest MARD in the low
(B80 mg/dL [B4.4 mmol/L]), middle (81–180
mg/dL [4.5–10.0 mmol/L]), and high
([180 mg/dL [ 10.0 mmol/L]) glucose ranges,
and was statistically significantly lower than the
other BGMSs, except for the ACP BGMS in the
low and middle glucose ranges.
Parkes-Consensus Error Grid analysis can be
used to assess the clinical impact of inaccurate
blood glucose results. In this study, all BGMS
results were within Zone A or Zone B of the
Parkes-Consensus Error Grid, with the majority
([94%) within Zone A across groups. Zone A of
the Parkes-Consensus Error Grid indicates no
effect on clinical action, and Zone B indicates
altered clinical action with little or no effect on
clinical outcome [12]. There were no results
within Zones C, D, or E; results in these zones
would indicate altered clinical action with
increasingly severe effects on clinical outcome.
In addition to the choice of meters for
evaluation, comparative analyses of meter
accuracy may involve differences in study
design. Such differences should be
considered when assessing the results of
comparative analyses. For example, meters
may be compared based on their ability to
fulfill ISO accuracy criteria or using MARD
analysis. Being continuously valued (i.e., a
decimal number), MARD facilitates the use of
powerful methods for comparing multiple
meters simultaneously (e.g., ANOVA).
Furthermore, as the clinical risk associated
with meter inaccuracy varies depending on
blood glucose concentration, evaluation of
meter accuracy in the low, middle, and high
glucose ranges in addition to the overall
glucose range provides a more complete
assessment of accuracy than does evaluation
in the overall glucose range only.
As patients with diabetes often have
comorbidities such as hyperlipidemia or
chronic kidney disease and may also be taking
multiple medications [22, 23], health care
providers and people with diabetes should also
be aware of agents that could interfere with the
accuracy of blood glucose results (Table 4). For
example, maltose can interfere with some
SMBG systems, leading to anomalously high
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glucose measurements that could mask
hypoglycemia or give an inaccurate indication
of hyperglycemia [3]. Maltose can be found in
certain immunoglobulin products, and it is a
metabolic by-product of the icodextrin that is
used in peritoneal dialysis.
Chronic diseases, including diabetes, present
serious health concerns, and their prevalence is
increasing in low-, middle-, and high-income
countries [24]. Relatively simple and cost-
effective steps can be taken to prevent or
significantly delay the onset of diabetes and its
complications [25]. For people with diabetes,
treatment and clinical monitoring to achieve
glycemic and metabolic control are core
components of effective diabetes care [25].
However, contributing factors to suboptimal
glycemic control include underutilization of
blood glucose data and the use of glycated
hemoglobin as the sole measure of glycemic
control [26]. SMBG is an integral component of
diabetes management and helps people with
Fig. 1 Modiﬁed Bland-Altman plots of the difference of
BGMS results from laboratory reference results for a CP,
b ACA, c ACP, d FF, and e OTSS. BGMS blood glucose
monitoring system, CP CONTOURPLUS, ACA Accu-
Chek Active, ACP Accu-Chek Performa, FF FreeStyle
FreedomTM, OTSS OneTouch SelectSimpleTM, YSI
Yellow Springs Instruments. Dashed lines ±15 mg/dL
(±0.8 mmol/L) or ±15% of the reference result for
samples with YSI glucose concentrations \100 mg/dL
(\5.6 mmol/L) and C100 mg/dL (C5.6 mmol/L),
respectively
b
Table 3 Parkes-Consensus Error Grid analysis of BGMS results
Meter system Number of results within error grid zones
Zone A Zone B Zones C, D, and E
CP 313/314 (99.7%) 1/314 (0.3%) 0/314 (0%)
ACA 308/314 (98.1%) 6/314 (1.9%) 0/314 (0%)
ACP 312/314 (99.4%) 2/314 (0.6%) 0/314 (0%)
FF 296/314 (94.3%) 18/314 (5.7%) 0/314 (0%)
OTSS 296/314 (94.3%) 18/314 (5.7%) 0/314 (0%)
BGMS blood glucose monitoring system, CP CONTOURPLUS, ACA Accu-Chek Active, ACP Accu-Chek Performa,
FF FreeStyle FreedomTM, OTSS OneTouch SelectSimpleTM
Table 4 Comparison of BGMS speciﬁcations
Meter system Test strip name Test strip chemistry Interference from oxygen [3, 31]
CP CP test strips FAD-GDH Not sensitive
ACA ACA test strips PQQ-GDH Not sensitive
ACP ACP test strips PQQ-GDH Not sensitive
FF FL test strips FAD-GDH Not sensitive
OTSS OTS test strips GO Sensitive
BGMS blood glucose monitoring system, CP CONTOURPLUS, FAD ﬂavin adenine dinucleotide, GDH glucose
dehydrogenase, ACA Accu-Chek Active, PQQ pyrroloquinoline quinone, ACP Accu-Chek Performa, FF FreeStyle
FreedomTM, FL FreeStyle LiteTM, OTSS OneTouch SelectSimpleTM, OTS OneTouch Select, GO glucose oxidase
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diabetes to attain better blood glucose control
[1, 2], especially when they are educated about
how to act on their results [5, 9, 27, 28]. Along
with the importance of health care providers
educating patients about proper SMBG
technique, advances in SMBG technology can
help minimize inaccuracy of blood glucose
results [5, 9, 20].
The primary objective of this study was
evaluation of all samples (unmodified and
modified); however, it is recognized that
glucose oxidase–based systems (e.g., OTSS) are
sensitive to interference from oxygen in the
sample [3, 20, 29, 30], as may occur during
sample modification. In light of this
recognition, a sub-analysis on unmodified
samples was performed, yielding similar results
and suggesting limited impact of blood sample
modification on results derived from glucose
oxidase–based systems in this study.
A potential limitation of this study is that
there is a finite number of BGMSs that can
realistically be compared in a single study. It is
possible that the results of the study may have
been different if another group of BGMSs had
been selected. However, based on the design of
the study, it would not have been feasible to
conduct the study using a larger group of
BGMSs, as it was important to minimize the
time elapsed from the first meter test to the last
meter test of a given blood sample to ensure
accurate comparisons. For this study, BGMSs
were selected to represent the most relevant
comparators for the CP BGMS. Another
potential limitation of the study is that only
1 lot of test strips was used, a noteworthy
consideration given that variation between test
strip lots may impact the apparent accuracy of a
BGMS [14]. At the same time, however, using 1
test strip lot reduces variability/noise in the
results.
CONCLUSIONS
The results of this study showed the CP BGMS
had a lower mean difference from the reference
value than all other systems tested across all
glucose ranges. The technologic aspects of the
system itself are contributors to the accuracy of
the CP BGMS observed in this study. As people
with diabetes learn more about how the use of
their blood glucose data can enable improved
glycemic control, use of the most accurate
BGMS may further contribute a significant
impact toward helping people manage their
diabetes more effectively by making better
informed decisions.
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